General
Preferred name
EPALRESTAT
Synonyms
ONO2235 ()
BNV-222 ()
ONO-2235 ()
Epalrestat (ONO-2235) ()
DIEPALRESTAT CHOLINE ()
Aldonil ()
Kinedak ()
Tanglin ()
Aldorin ()
Epalrestat-d5 ()
P&D ID
PD000498
CAS
82159-09-9
1665300-21-9
Tags
available
drug
drug candidate
First approval
1992
Drug indication
Breast cancer
Pain
Diabetic neuropathy
Drug Status
approved
investigational
Max Phase
2.0
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Epalrestat (ONO-2235) is an orally active inhibitor of aldose reductase (AR). It was originally developed for potential to treat peripheral nerve (e.g. diabetic) damage , but was later evaluated for anti-cancer action . Epalrestat has been shown to inhibit several isozymes of the CYP4 family in vitro , and is most potent at CYP4A11 .
(GtoPdb)
DESCRIPTION
Epalrestat is an orally active aldose reductase inhibitor that acts on diabetic neuropathy[1][2][3].
PRICE
29
DESCRIPTION
Epalrestat (ONO2235), an aldose reductase inhibitor, is well tolerated in Long-term therapy. It can effectually ameliorate the associated symptoms of diabetic neuropathy and delay the progression of the disease, particularly in patients with limited microangiopathy and good glycemic control.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
19
AdooQ Bioactive Compound Library
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2021/22
Drug Repurposing Hub
DrugBank
DrugCentral
DrugCentral Approved Drugs
DrugMAP Approved Drugs
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
MedChem Express Bioactive Compound Library
NPC Screening Collection
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
35
Molecular Weight
319.03
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
1
Rotatable Bonds
4
Ring Count
2
Aromatic Ring Count
1
cLogP
2.92
TPSA
57.61
Fraction CSP3
0.13
Chiral centers
0.0
Largest ring
6.0
QED
0.68
Structural alerts
1
ene_rhod_A(235)
[#7]-1-[#6](=[#16])-[#16]-[#6](=[#6])-[#6]-1=[#8]
PAINS Family A
Related compounds
Custom attributes
(extracted from source data)
Target
Aldose Reductase
AKR1B1
Aldose Reductase,Carbohydrate Metabolism
MOA
Reductase inhibitor
Aldose reductase inhibitor
Pathway
Enzyme
Endocrinology/Hormones
Metabolism
Metabolic Enzyme/Protease
Indication
diabetic nephropathy
Therapeutic Class
Hypoglycemic Agents
Source data
